|Description||LCZ696 is a novel single molecule comprising molecular moieties of valsartan and NEP inhibitor prodrug AHU377 (1:1 ratio). Oral administration of LCZ696 caused dose-dependent increases in atrial natriuretic peptide immunoreactivity (due to NEP inhibition) in Sprague-Dawley rats and provided sustained, dose-dependent blood pressure reductions in hypertensive double-transgenic rats. In healthy participants, a randomized, double-blind, placebo-controlled study (n = 80) of single-dose (200-1200 mg) and multiple-dose (50-900 mg once daily for 14 days) oral administration of LCZ696 showed that peak plasma concentrations were reached rapidly for valsartan (1.6-4.9 hours), AHU377 (0.5-1.1 hours), and its active moiety, LBQ657 (1.8-3.5 hours). LCZ696 is superior to valsartan alone in reducing blood pressure. Preliminary results from a Phase II trial showed that LCZ696 reduced NT-proBNP to a greater extent than valsartan alone, and in addition LCZ696 had beneficial effects on symptoms.|
|Related CAS||149709-62-6 (free acid)|
|Appearance||white to off-white solid powder|
|Synonyms||calcium 4-(((2S,4R)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoate; AHU337; AHU-337; AHU 337; LCZ696; LCZ 696; LCZ696; Sacubitril|
SQ28603 is a selective neutral endopeptidase (NEP 18.104.22.168) inhibitor.
AHU-377 hemicalcium salt
LCZ696 is a novel single molecule comprising molecular moieties of valsartan and NEP inhibitor prodrug AHU377 (1:1 ratio). Oral administration of LCZ696 caused ...
Sacubitril, also known as AHU377, is a first-in-class medicine that contains a neprilysin (NEP) inhibitor (sacubitril) and an angiotensin II (Ang-II) receptor b...
Ecadotril is a neutral endopeptidase(NEP) inhibitor and determined by the presence of peptidase family M13 as a neutral endopeptidase inhibited by phosphoramido...
Sacubitril, also known as AHU377 or LCZ696, is angiotensin receptor neprilysin inhibitor being studied for use in combination with valsartan for heart failure. ...